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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
EffEXT™ and maintenance of normal joint mobility pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) No 
1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and Allergies 
(NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to EffEXT™ and 
maintenance of normal joint mobility. The Panel considers that EffEXT™, which is standardised pure krill oil, is 
sufficiently characterised. The claimed effect proposed by the applicant is “contributes to support joint 
flexibility”. The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. 
The applicant identified one human intervention study as being pertinent to the health claim. The Panel notes that 
chronic inflammation was an inclusion criterion of the study, that a significant number of the patients recruited 
were reported to have confirmed diagnosis of osteoarthritis, rheumatoid arthritis, or of both cardiovascular 
disease and osteoarthritis, and that the WOMAC osteoarthritis questionnaire was administered only to patients 
with arthritic disease (osteoarthritis or rheumatoid arthritis). The Panel also notes that no evidence which could 
justify the extrapolation of the results, obtained in patients with joint diseases characterised by chronic 
inflammation, to the target population, subjects without chronic joint diseases, was provided by the applicant. 
The Panel considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. The Panel concludes that a cause and effect relationship has not been established between the consumption 
of EffEXT™ and maintenance of normal joint mobility. 
© European Food Safety Authority, 2012 
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SUMMARY 
Following an application from Nutrilinks Sarl, submitted pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006 via the Competent Authority of Belgium, the Panel on Dietetic Products, Nutrition and 
Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to EffEXT™ and maintenance of normal joint mobility. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. 
The food that is the subject of the health claim is EffEXT™, which is standardised pure krill oil. The 
Panel considers that EffEXT™ is sufficiently characterised. 
The claimed effect proposed by the applicant is “contributes to support joint flexibility”. The target 
population proposed by the applicant is adults with “sensitive joints”. The Panel considers that the 
health claim refers to the maintenance of joint mobility in subjects without chronic joint diseases, and 
does not include the treatment of chronic joint diseases. The Panel considers that maintenance of 
normal joint mobility is a beneficial physiological effect. 
The applicant identified one human intervention study as being pertinent to the health claim. 
The study was a randomised, double-blind, placebo-controlled 30-day trial in 90 patients who had 
confirmed diagnosis of at least one chronic inflammatory disease (i.e. cardiovascular disease, 
rheumatoid arthritis (RA), osteoarthritis (OA)) and steadily (i.e. for three consecutive weeks) 
increased plasma concentrations of C-reactive protein (CRP 10.0 mg/l). Patients were randomised to 
consume daily 300 mg Neptune Krill Oil™ (n=45) or a placebo (n=45). The primary outcome of the 
study was blood concentration of CRP. As a secondary outcome, patients with arthritic disease 
(having either RA or OA) were asked to complete the Western Ontario and McMaster Universities 
(WOMAC) osteoarthritis questionnaire. 
The Panel notes that chronic inflammation was an inclusion criterion of the study, that a significant 
number of the patients recruited were reported to have confirmed diagnosis of OA, RA, or of both 
cardiovascular disease and OA, and that the WOMAC osteoarthritis questionnaire was administered 
only to patients with arthritic disease (OA or RA). In addition, the Panel considers that although the 
criteria used for the diagnosis of OA or RA were not specified in the publication, a chronic 
inflammatory disease of the joints is likely in patients with chronically elevated CRP concentrations 
of 10 mg/l and mean WOMAC scores for pain, stiffness and functional impairment ranging from 
2.85 to 3.45 (the worst score being 4) at baseline. The Panel also notes that no evidence which could 
justify the extrapolation of the results, obtained in patients with joint diseases characterised by 
chronic inflammation, to the target population, subjects without chronic joint diseases, was provided 
by the applicant. The Panel considers that no conclusions can be drawn from this study for the 
scientific substantiation of the claim. 
The Panel notes that no studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of EffEXT™ and maintenance of normal joint mobility. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA  
 The application was received on 06/03/2012. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. 
 On 04/04/2012, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 The applicant provided the missing information on 17/04/2012. 
 The scientific evaluation procedure started on 30/04/2012. 
 On 13/09/2012, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application. The clock was stopped on 21/09/2012 
and restarted on 06/10/2012, in compliance with Article 18(3) of Regulation (EC) No 
1924/2006. 
 On 17/10/2012, EFSA received the requested information (which was made available to 
EFSA in electronic format on 08/10/2012). 
 During its meeting on 28/11/2012, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to EffEXT™ and 
maintenance of normal joint mobility. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
opinion on the scientific substantiation of a health claim related to: EffEXT™ and maintenance of 
normal joint mobility. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of EffEXT™, a positive assessment of its safety, nor a decision on whether EffEXT™ is, or is 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Nutrilinks Sarl, Chemin de Beau-rivage 7, P.O. Box 96, CH-1000 
Lausanne 21, Switzerland. 
Food/constituent as stated by the applicant 
According to the applicant, EffEXT™, which is a standardised pure krill oil extract. 
Health relationship as claimed by the applicant 
According to the applicant, the claim relates to the improvement of joint flexibility. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “contributes to support joint 
flexibility”. 
The following alternative wordings were proposed: “supports joint health”, “is fast-acting and 
clinically proven to improve joint flexibility”, “is fast-acting and clinically proven to reduce joint 
stiffness”, “is beneficial to help maintain normal (joint) inflammation and improve (joint) function 
and comfort”, “is active (by improving joint flexibility/reducing joint stiffness) after only 7 days of 
daily consumption”, “active from 7 days”. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 300 mg EffEXT™ per day, preferably in the morning, for 
30 consecutive days. The target population is adults presenting with sensitive joints. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food that is the subject of the health claim is EffEXT™, which is standardised pure krill oil. 
Krill oil is extracted from the crustacean Euphausia superba (Antarctic Krill) and has been authorised 
as a novel food ingredient
5
. The krill oil which is the subject of the claim complies with Commission 
Decision 2009/752/EC. The main constituents contained in the krill oil are phospholipids 
(≥42.0 g/100 g), omega-3 fatty acids (≥26.5 g/100 g), comprising eicosapentaenoic acid (EPA, C20:5, 
≥14.2 g/100 g) and docosahexaenoic acid (DHA, C22:6, ≥8.5 g/100 g), and saturated fatty acids 
(25.0±5 g/100 g). The content of esterified astaxanthin amounts to around 1,000 to 1,500 mg/kg. 
Phospholipids, fatty acids and astaxanthin can be measured in foods by established methods. 
Information on the stability and batch-to-batch variability of the product has been provided. 
The Panel considers that the food, EffEXT™, which is the subject of the health claim, is sufficiently 
characterised. 
                                                     
5  2009/752/EC: Commission Decision of 12 October 2009 authorising the placing on the market of a lipid extract from 
Antarctic Krill Euphausia superba as a novel food ingredient under Regulation (EC) No 258/97 of the European 
Parliament and of the Council (notified under document C(2009) 7647), OJ L 268, 13.10.2009, p. 33–34. 
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2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “contributes to support joint flexibility”. The target 
population proposed by the applicant is adults with “sensitive joints”. A definition for “sensitive 
joints” was not provided. 
The Panel considers that the health claim refers to the maintenance of joint mobility in subjects 
without chronic joint diseases, and does not include the treatment of chronic joint diseases. 
The Panel considers that maintenance of normal joint mobility is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in Pubmed, ScienceDirect, Blackwell Synergy, Wiley 
InterScience, Mary Ann Liebert, Scirus, IBIDS, SciFinder Scholar, Pascal, Google and SCOPUS 
using the search terms [“Neptune Krill Oil”] AND [“arthritic symptoms” OR “joint”] for publications 
between January 2000 and May 2011, as well as hand searches in specialised libraries and general 
web research, to identify human intervention studies conducted with Neptune Krill Oil™ in 
volunteers presenting with “sensitive joints”. Exclusion criteria and the meaning of “sensitive joints” 
were not specified. The Panel notes the limited scope of the literature search performed. 
The applicant identified one human intervention study as being pertinent to the health claim (Deutsch, 
2007). 
The study (Deutsch, 2007) was a randomised, double-blind, placebo-controlled 30-day trial in 
90 patients who had confirmed diagnosis of at least one chronic inflammatory disease (i.e. cardio-
vascular disease, rheumatoid arthritis (RA), osteoarthritis (OA)) and steadily (i.e. for three 
consecutive weeks) increased plasma concentrations of C-reactive protein (CRP 10.0 mg/l), and who 
were recruited from the practices of primary care physicians. In order to avoid the inclusion of 
patients with acute inflammation, CRP was measured weekly for three consecutive weeks (i.e. 
screening period). Patients who maintained a CRP of at least 10 mg/l, without fluctuations higher than 
0.5 mg/l, were included in the study and randomised to consume daily 300 mg Neptune Krill Oil™ 
(NKO™; n=45, 20 women, mean age 54.6 years) or a placebo (microcrystalline cellulose; n=45, 23 
women, mean age 55.3 years). Patients were allowed to take acetaminophen (paracetamol) as a rescue 
analgesic medication for severe pain throughout the trial. The primary outcome of the study was 
blood concentration of CRP. As a secondary outcome, patients with arthritic disease (having either 
RA or OA) were asked to complete the Western Ontario and McMaster Universities (WOMAC) 
osteoarthritis questionnaire, which has been validated to evaluate joint pain, stiffness and loss of 
function related to osteoarthritis of the knee and hip and has been used for the evaluation of the effect 
of different interventions on the treatment of osteoarthritis. The WOMAC osteoarthritis score has 3 
subscales with 24 items; 5 items assessing pain, 2 items for stiffness, and 17 items measuring physical 
function. The WOMAC can be scored both separately for each subscale and together to give a 
composite score. The scale employed in this study to quantify patient global assessment of disease 
activity was the Likert scale, a 5-point scale in which 0 represents the best outcome and 4 the worst. 
The applicant was requested to provide evidence on whether results obtained in patients with chronic 
inflammatory joint diseases (RA or OA) could be extrapolated to the target population, subjects 
without chronic inflammatory diseases of the joints. In reply, the applicant acknowledged that the 
primary outcome of the study was changes in plasma concentrations of CRP in a study population 
with chronically elevated CRP concentrations ( 10 mg/l). However, the applicant claims that the 
publication did not specify symptomatic or radiologic criteria for the diagnosis of RA or OA, that 
patients were only taking acetaminophen or acetylsalicylic acid at recruitment and did not use any 
rescue medication for severe pain during the study except acetaminophen, and that patient withdrawal 
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rate from the study was very low, which, according to the applicant, would indicate that only subjects 
having mild to moderate “arthritic-like” symptoms had been recruited. 
The Panel notes that the publication (Deutsch, 2007) clearly specifies that chronic inflammation 
defined as plasma concentrations of CRP 10 mg/l for three consecutive weeks was an inclusion 
criterion of the study, that a significant number of the patients recruited were reported to have 
confirmed diagnosis of OA (18 and 16 in the intervention and control groups, respectively), of RA (10 
and 12 patients in the intervention and control groups, respectively), or of both cardiovascular disease 
and OA (12 and 10 patients in the intervention and control groups, respectively), and that the 
WOMAC questionnaire was administered only to patients with arthritic disease (OA or RA). In 
addition, the Panel considers that although the criteria used for the diagnosis of OA or RA were not 
specified in the publication, a chronic inflammatory disease of the joints is likely in patients with 
chronically elevated CRP concentrations of 10 mg/l and mean WOMAC scores for pain, stiffness 
and functional impairment ranging from 2.85 to 3.45 (the worst score being 4) at baseline. The Panel 
also notes that no evidence which could justify the extrapolation of the results, obtained in patients 
with joint diseases characterised by chronic inflammation, to the target population, subjects without 
chronic joint diseases, was provided by the applicant. The Panel considers that no conclusions can be 
drawn from this study for the scientific substantiation of the claim. 
The Panel notes that no studies from which conclusions could be drawn for the scientific 
substantiation of the claim were provided by the applicant. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of EffEXT™ and maintenance of normal joint mobility. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 
 The food, EffEXT™, which is the subject of the health claim, is sufficiently characterised. 
 The claimed effect proposed by the applicant is “contributes to support joint flexibility”. The 
target population proposed by the applicant is adults with “sensitive joints”. The health claim 
refers to the maintenance of joint mobility in subjects without chronic joint diseases, and does 
not include the treatment of chronic joint diseases. Maintenance of normal joint mobility is a 
beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of EffEXT™ 
and maintenance of normal joint mobility. 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on EffEXT™ and maintenance of normal joint mobility pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0339_BE). March 2012. Submitted 
by Nutrilinks Sarl. 
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GLOSSARY/ABBREVIATIONS 
CRP  C-reactive protein 
OA  Osteoarthritis 
RA  Rheumatoid arthritis 
WOMAC Western Ontario and McMaster Universities 
